Cost Effectiveness of Caplacizumab in Acquired Thrombotic Thrombocytopenic Purpura

被引：1
|
作者：
Goshua, George
Sinha, Pranay
Hendrickson, Jeanne E.
Tormey, Christopher A.
Bendapudi, Pavan
Lee, Alfred Ian
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-138515
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Cost-effectiveness analysis of caplacizumab in the new standard of care for immune Thrombotic Thrombocytopenic Purpura in Italy
    Di Minno, Giovanni
    Ravasio, Roberto
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2021, 8 : 43 - 52
  • [42] COST-EFFECTIVENESS OF CAPLACIZUMAB FOR THROMBOTIC THROMBOCITOPENIC PURPURA IN BRAZIL
    Simoes, Correa Galendi J.
    Rasch, H.
    Caramori, C. A.
    Gaiolla, R. D.
    Mueller, D.
    Nunes-Nogueira, V. S.
    VALUE IN HEALTH, 2024, 27 (12) : S71 - S71
  • [43] A safe and effective use of caplacizumab in pregnancy-related acquired thrombotic thrombocytopenic purpura
    Odetola, Oluwatobi
    Martin, Karlyn A.
    Dreyer, Marie
    Rajan, Priya
    Zakarija, Anaadriana
    Stein, Brady L.
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 202 (04) : 879 - 882
  • [44] Brazilian experience with caplacizumab in acquired thrombotic thrombocytopenic purpura: outcomes of the expanded access program
    Boechat, Tiago de Oliveira
    Farias, Joao Samuel de Holanda
    Ribeiro, Eduardo Flavio Oliveira
    de Andrade, Michaela Larissa Lobo
    ANNALS OF HEMATOLOGY, 2023, 102 (06) : 1581 - 1588
  • [45] CAPLACIZUMAB Anti-von Willebrand factor Treatment of acquired thrombotic thrombocytopenic purpura
    Haddley, K.
    DRUGS OF THE FUTURE, 2016, 41 (10) : 589 - 594
  • [46] Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab
    Sukumar, Senthil
    George, James N.
    Cataland, Spero R.
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (04) : E76 - E77
  • [47] Brazilian experience with caplacizumab in acquired thrombotic thrombocytopenic purpura: outcomes of the expanded access program
    Tiago de Oliveira Boechat
    João Samuel de Holanda Farias
    Eduardo Flávio Oliveira Ribeiro
    Michaela Larissa Lobo de Andrade
    Annals of Hematology, 2023, 102 : 1581 - 1588
  • [48] Effectiveness and safety of caplacizumab in acquired thrombotic thrombocytopenic purpura: health technology assessment and classification according to the methodology established in Colombia
    Soto-Mora, Jahir A.
    Gomez-Espitia, Lina M.
    Lasalvia, Pieralessandro
    Moreno, Camilo A. Castellanos A.
    Vanegas, Carol A. Casallas A.
    Gutierrez, Sergio A. Londono A.
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2023, 39 (01)
  • [49] Use of caplacizumab in a child with refractory thrombotic thrombocytopenic purpura
    Bhoopalan, Senthil Velan
    Hankins, Jane
    George, James
    Ryder, Alex
    Onder, Ali Mirza
    Puri, Latika
    PEDIATRIC BLOOD & CANCER, 2019, 66 (07)
  • [50] Caplacizumab: a change in the paradigm of thrombotic thrombocytopenic purpura treatment
    le Besnerais, Maelle
    Veyradier, Agnes
    Benhamou, Ygal
    Coppo, Paul
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (11) : 1127 - 1134
12345